Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

DTCFFBullishCorporate Developmentsnews

High materiality7/10

Defence Therapeutics adds seasoned finance executive to board, grants options

Sep 29, 2026, 3:25 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A strategic governance upgrade paired with a meaningful option grant can bolster investor confidence and signaling of capital-market readiness, despite modest near-term dilution.

AI summary

What happened, with direct paths to the underlying reporting

Defence Therapeutics appointed Sherry Aulin to its Board and Audit Committee, signaling stronger finance and governance as it advances its Accum platform. The company issued 400,000 incentive options at $0.40, with 200,000 vesting immediately and 200,000 after one year, indicating near-term dilution but alignment with shareholders. The move leverages Aulin's public-company experience to support capital-market execution and strategic planning.

Defence Therapeutics adds Sherry Aulin to its board and audit committee.
The company grants 400,000 incentive options at $0.40; 200k vested now, 200k in 1 year.
Aulin brings 20+ years in capital markets, ex-CFO of Xenon Pharmaceuticals.
Forward-looking statements accompany the release; approvals, capital, and market conditions cited.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.